Form 4 for DNTH Dianthus Therapeutics, Inc. /DE/
Accepted 2026-04-01 17:26:57 ET · period of report 2026-03-31 · accession 0001992324-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-04-01 17:26 | 2026-03-31 | DNTH | Savitz Ryan | EVP, CFO, CBO | M - OptEx | $11.74 | +114.4K | 114.4K | New | +$1.34M |
| DMT | 2026-04-01 17:26 | 2026-03-31 | DNTH | Savitz Ryan | EVP, CFO, CBO | S - Sale+OE | $83.00 | -114.4K | 0 | -100% | -$9.49M |
| DMT | 2026-04-01 17:26 | 2026-03-31 | DNTH | Savitz Ryan | EVP, CFO, CBO | M - OptEx | $0.00 | -114.4K | 80.0K | -59% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-31 | M | A | 74,367 | $8.44 | 74,367 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. |
| 2 | Common | Common Stock | 2026-03-31 | M | A | 40,000 | $17.88 | 114,367 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. |
| 3 | Common | Common Stock | 2026-03-31 | S | D | 1,390 | $78.33 | 112,977 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. (F2) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.74 to $78.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 4 | Common | Common Stock | 2026-03-31 | S | D | 21,825 | $78.86 | 91,152 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. (F3) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.74 to $79.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 5 | Common | Common Stock | 2026-03-31 | S | D | 1,485 | $80.25 | 89,667 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. (F4) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.11 to $81.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 6 | Common | Common Stock | 2026-03-31 | S | D | 800 | $81.36 | 88,867 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. (F5) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.15 to $81.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 7 | Common | Common Stock | 2026-03-31 | S | D | 2,366 | $82.84 | 86,501 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. (F6) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.25 to $83.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 8 | Common | Common Stock | 2026-03-31 | S | D | 59,800 | $83.90 | 26,701 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. (F7) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.25 to $84.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 9 | Common | Common Stock | 2026-03-31 | S | D | 19,469 | $84.57 | 7,232 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. (F8) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.25 to $85.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 10 | Common | Common Stock | 2026-03-31 | S | D | 7,232 | $85.54 | 0 | D | — | — | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. (F9) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.25 to $85.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 11 | Derivative | Stock Option (Right to Buy) | 2026-03-31 | M | D | 74,367 | $0.00 | 10,399 | D | $8.44 · — to 2032-06-06 | 74,367 Common Stock | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. (F10) The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
| 12 | Derivative | Stock Option (Right to Buy) | 2026-03-31 | M | D | 40,000 | $0.00 | 80,000 | D | $17.88 · — to 2034-01-23 | 40,000 Common Stock | (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. (F11) The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |